Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Healthways Inc Reaffirms FY 2013 Guidance; Comments On H2 2013 Revenue Guidance


Thursday, 18 Apr 2013 04:00pm EDT 

Healthways Inc affirmed its previously issued guidance for fiscal 2013. The Company's guidance for fiscal 2013 revenues is a range of $710 million to $750 million. The Company expects its revenues to grow sequentially throughout 2013, particularly in the second half of the year. This sequential growth is driven primarily by the contracts signed in 2012 that are expected to ramp for as long as 24 to 36 months before reaching an average target revenue run rate. The Company's guidance for net income per diluted share remains in the range of $0.25 to $0.35. Consistent with guidance for 2013 EBITDA, the Company expects net income per diluted share to ramp through the sequential quarters of 2013, including a net loss of approximately $0.05 per share for the second quarter of the year before returning to profitability in the third quarter. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $727 million and EPS of $0.28 for fiscal 2013. 

Company Quote

17.39
0.11 +0.64%
30 Jul 2014